Medical technology company Pexa is carrying out a directed new share issue of 31.25 million B shares at a subscription price of SEK 0.32 per share, thereby raising SEK 10 million before issue costs. This is stated in a press release.The issue is subscribed by Hallberg Management, which is owned by HealthInvest founder Anders Hallberg. Following approval from the Inspectorate of Strategic Products, Hallberg Management is expected to own approximately 20.1 percent of the capital and 19.6 percent of the votes in Pexa. "I am impressed by Pexa's technology, which makes it possible to collect samples from the smallest airways in a non-invasive way - a method already used by research groups around the world and which has resulted in some sixty scientific publications. It gives the company a strong foundation on the way toward clinical applications in, for example, lung cancer and COPD, a market that comprises several million patients globally. I see clear potential for the technology to move from research to clinical everyday practice, which could create significant value for both affected patients and Pexa's shareholders. It feels fantastic to be part of that journey," says Anders Hallberg in a comment.The issue entails dilution of approximately 20 percent, and the capital is to be used to strengthen the company's commercialization and the implementation of larger customer projects.